Article Sidebar
Main Article Content
Abstract
EKSPRESI CD30 PADA PASIEN DIFFUSE LARGE B-CELL LYMPHOMA
DI RSUP DR. KARIADI SEMARANG
Jessica Winoto1; Udadi Sadhana2; Dik Puspasari2; Siti Amarwati2; Devia Eka Listiana2; Hermawan Istiadi2
Residen Departemen Patologi Anatomi, Fakultas Kedokteran Universitas Diponegoro, Semarang, Indonesia1; Staf pengajar Departemen Patologi Anatomi, Fakultas Kedokteran Universitas Diponegoro, Semarang, Indonesia2
Corresponding email: jessicawin11@gmail.com
Abstrak
Latar Belakang: Diffuse Large B-Cell Lymphoma (DLBCL) merupakan penyakit heterogen dengan berbagai morfologi, sifat biologi dan klinis, yang memiliki respon terapi bervariasi. Beberapa penelitian melaporkan adanya ekspresi CD30 pada DLBCL berhubungan dengan ketahanan hidup yang lebih baik. Namun hal ini masih perlu dilakukan penelitian lebih lanjut. Tujuan penelitian ini untuk mengevaluasi ekspresi CD30 pada pasien DLBCL di RSUP Dr. Kariadi.
Metode penelitian: Penelitian ini mengevaluasi ekspresi CD30 pada 35 pasien DLBCL di RSUP Dr. Kariadi periode Januari 2017 hingga Desember 2017 menggunakan cut off >0%. Data klinik yang diambil yaitu usia saat terdiagnosis, lokasi tumor, stadium penyakit, subtipe sel asal, dan ketahanan hidup 2 tahun. Analisis data menggunakan uji chi square.
Hasil: Dari 35 kasus, CD30 diekspresikan oleh 13 kasus (37.1%). Ekspresi CD30 lebih tinggi pada pasien dengan usia ?60 tahun (P=0.03), lokasi ekstranodal (P=0.78), stadium awal (P=0.89), dan subtipe non-GCB (P=0.97). Kelompok CD30 positif memiliki ketahanan hidup yang lebih baik dibandingkan CD30 negatif (P=0.90).
Kesimpulan: Ekspresi CD30 memiliki hubungan yang bermakna dengan usia ?60 tahun. Pasien DLBCL dengan CD30 positif memiliki ketahanan hidup yang lebih baik dibandingkan CD30 negatif, namun tidak bermakna.
Kata Kunci : DLBCL, CD30, ketahanan hidup
CD30 EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS
IN KARIADI GENERAL HOSPITAL SEMARANG
Jessica Winoto1; Udadi Sadhana2; Dik Puspasari2; Siti Amarwati2; Devia Eka Listiana2; Hermawan Istiadi2
Resident of Anatomical Pathology Department, Faculty of Medicine Diponegoro University, Semarang Indonesia1; Lecturer of Anatomical Pathology Department, Faculty of Medicine Diponegoro University, Semarang Indonesia2
Corresponding email: jessicawin11@gmail.com
Abstract
Background: Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogenous disease containing morphology, biologically dan clinically distinctive subgroups that show variable response to therapy. Many studies showed that CD30 expression in DLBCL is associated with superior overall survival. However, prognostic value of CD30 expression in DLBCL still needs further studies. The aim of this study was to determine the expression of CD30 in DLBCL patients in Kariadi General Hospital.
Methods: This study identified CD30 expression in 35 cases of DLBCL diagnosed between January 2017 and December 2017, using cut off values >0%. Clinical data collected including age of diagnosis, tumour location, stage of disease, cell of origin subtype, and two-year overall survival. Data were analyzed using chi square test.
Results: CD30 expression was found in 13 (37.1%) cases. CD30 positivity was higher in age ?60 years (P=0.03), extranodal location (0.78), early stage (P=0.89), and non-GCB subtype (P=0.97). CD30-positve DLBCL had a better survival than CD30-negative DLBCL (P=0.90).
Conclusion: CD30 positivity was significantly associated with age ?60 years. CD30-positve DLBCL had a better survival than CD30-negative DLBCL, but not significant.
Keywords: DLBCL, CD30, overall survival
Article Details
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).